文献速递技术与安全腹部胸部CTMRUS乳腺X线

人工智能辅助检查在医学影像癌症检测中的有效性:系统综述与Meta分析

Effectiveness of Artificial Intelligence-Assisted Examination for Cancer Detection in Medical Imaging: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Am Coll Radiol · 2025-11-13

该系统综述与Meta分析检索七个数据库2017年1月1日至2024年6月30日的随机对照试验,纳入49项RCT覆盖七种癌症类型,其中79.6%(n=39)为结直肠癌。AI辅助检查对结直肠癌腺瘤(合并RR=1.22,95%CI:1.17-1.28,36项RCT)和息肉(合并RR=1.20,95%CI:1.14-1.26,28项RCT)检出率有提高,对食管癌、前列腺癌、肺癌可操作结节和乳腺癌的检出率也有统计学显著改善,但对胃癌和肝癌检出率无显著影响。作者结论认为AI辅助检查可能改善部分而非全部七种癌症的检出率,且患者中心结局明显缺乏,未来研究应优先评估AI对患者中心结局的影响。

要点

  • 结直肠癌:AI辅助使腺瘤检出率合并RR=1.22(95%CI:1.17-1.28,36项RCT)、息肉检出率合并RR=1.20(95%CI:1.14-1.26,28项RCT)。
  • 肺癌:AI辅助使可操作肺结节检出率RR=2.38(95%CI:1.25-4.55,1项RCT);前列腺癌合并RR=1.40(95%CI:1.10-1.77,1项3臂RCT)。
  • 胃癌和肝癌:AI辅助检查对检出率无显著影响;患者中心结局明显缺乏。

核心结论

  • AI辅助检查可能改善七种癌症中部分癌症的检出率而非全部,患者中心结局明显缺乏,未来研究应优先评估AI对患者中心结局的影响。

研究设计与样本

  • 系统综述与Meta分析,检索七个数据库2017年1月1日至2024年6月30日的随机对照试验,纳入49项RCT覆盖七种癌症类型,其中79.6%(n=39)为结直肠癌。

诊断标准与关键数值

  • 结直肠癌腺瘤检出率:合并RR=1.22(95%CI:1.17-1.28),基于36项RCT。
  • 结直肠癌息肉检出率:合并RR=1.20(95%CI:1.14-1.26),基于28项RCT。
  • 食管癌高危病变检出率:RR=2.01(95%CI:1.06-3.80),基于1项RCT。
  • 食管浅表鳞状细胞癌及癌前病变检出率:RR=1.38(95%CI:1.03-1.86),基于1项RCT。
  • 前列腺癌检出率:合并RR=1.40(95%CI:1.10-1.77),基于1项3臂RCT。

局限性

  • 患者中心结局明显缺乏,而这对评估对患者的最终获益至关重要。
  • 胃癌和肝癌的检出率未观察到显著效果。
  • 49项RCT中79.6%(n=39)为结直肠癌,其他癌症类型的证据多基于单项RCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the effectiveness of artificial intelligence (AI)-assisted examination for cancer detection in medical imaging.

METHODS: We searched seven databases from January 1, 2017, until June 30, 2024, to identify randomized controlled trials (RCTs). The primary outcomes were detection rates and patient-centered outcomes. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated.

RESULTS: We included 49 RCTs covering seven cancer types, with 79.6% (n = 39) being colorectal cancer. AI-assisted examination showed varying effects on detection rates across different cancer types. Specifically, regarding colorectal cancer, AI increased detection rates for both adenoma (pooled RR = 1.22, 95% CI: 1.17-1.28, 36 RCTs) and polyp (pooled RR = 1.20, 95% CI: 1.14-1.26, 28 RCTs). For esophageal cancer, positive effects were also observed on the detection rates of high-risk esophageal lesions (RR = 2.01, 95% CI: 1.06-3.80, 1 RCT) as well as superficial esophageal squamous cell carcinoma and precancerous lesions (RR = 1.38, 95% CI: 1.03-1.86, 1 RCT). Moreover, statistically significant improvement in detection rates were observed in prostate cancer (pooled RR = 1.40, 95% CI: 1.10-1.77, 1 RCT with 3 arms), actionable lung nodules (RR = 2.38, 95% CI: 1.25-4.55, 1 RCT) for lung cancer, and breast cancer (RR = 1.20, 95% CI: 1.00-1.45, 1 RCT). However, no significant effect was observed on the detection rates of gastric or liver cancer.

CONCLUSIONS: AI-assisted examinations may improve certain detection rates but not all among seven cancer types. There is a notable lack of patient-centered outcomes, crucial for evaluating the ultimate benefits to patients. Future research should give priority to assessing the impact of AI on patient-centered outcomes beyond diagnostic accuracy.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Song J, Gao Y, Liu W, et al. Effectiveness of Artificial Intelligence-Assisted Examination for Cancer Detection in Medical Imaging: A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2025. PMID: 41241061. doi:10.1016/j.jacr.2025.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。